NCT00210483View on ClinicalTrials.gov

A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents

PHASE3CompletedINTERVENTIONAL

Enrollment

866

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

July 31, 2005

Conditions

Migraine

Interventions

DRUG

almotriptan malate

All Listed Sponsors

collaborator

Ortho-McNeil Neurologics, Inc.

INDUSTRY

lead

Janssen-Ortho LLC

INDUSTRY

NCT00210483 - A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents | Biotech Hunter | Biotech Hunter